TAME Trial Explores Metformin's Potential to Extend Human Lifespan
The Targeting Aging with Metformin (TAME) trial is set to explore whether metformin, a long-established medication for type 2 diabetes, can also slow biological aging. This significant study, spearheaded by the American Federation for Aging Research (AFAR), will take place across 14 leading research institutions in the United States and will involve 3,000 participants aged between 65 and 79 who do not have diabetes. The trial is designed as a double-blind, randomized, placebo-controlled study, where half of the participants will receive a standard daily dose of metformin (1,500 mg/day), while the other half will receive a placebo. If funding is secured, the trial will span six years, focusing on delaying aging and related diseases. It is crucial to note that the use of metformin for longevity is currently off-label and has not received FDA approval for this purpose.
In a recent discussion with Medical News Today, two experts, Dr. David Cutler and Dr. Diogo Barardo, provided insights into the potential of metformin in the context of human longevity. Metformin is known for its safety, low cost, and effectiveness in treating type 2 diabetes, functioning by improving insulin sensitivity and regulating energy metabolism. A study published in the journal Cell in 2024 found that metformin slowed aging in male monkeys by approximately six years over a 40-month period, hinting at its potential effects on longevity.
Experts suggest that metformin may influence several biological processes associated with aging, including mitochondrial function, inflammation, and cellular maintenance. Dr. Cutler noted that while there is an intriguing case for metformin's ability to slow biological aging, the current evidence primarily stems from observational studies and animal models, which do not definitively prove its efficacy in humans.
Dr. Barardo emphasized the need for robust clinical trials to establish metformin's potential longevity benefits. He pointed out that while metformin can activate AMPK, a cellular energy sensor, and reduce mTOR signaling, which may support cellular maintenance processes, the evidence is not yet strong enough to recommend it for longevity in healthy individuals.
Both experts cautioned against self-prescribing metformin for longevity, highlighting that the drug is not recommended for healthy individuals outside of clinical trials. Dr. Cutler stated that while metformin is generally safe, it can have side effects, including gastrointestinal issues and vitamin B12 deficiency, which can lead to more serious health problems.
Instead of relying on unproven longevity drugs, the experts recommend focusing on established lifestyle factors that contribute to health and longevity, such as regular physical activity, a balanced diet, adequate sleep, and effective management of chronic health conditions. Dr. Barardo reiterated the importance of adhering to WHO guidelines for physical activity, which suggest 150 to 300 minutes of moderate-intensity exercise weekly, alongside strength training on at least two days.
In conclusion, while the TAME trial represents a significant step in understanding the potential of metformin to influence aging, experts agree that more comprehensive research is necessary before any recommendations can be made regarding its use for longevity in the general population.




